The combination of both monoclonal antibodies, however, resulted in the killing of both EGFR and CD38 expressing tumor cells, demonstrating that single-specificity CAR-T cells can be used to simultaneously target multiple tumor antigens and kill heterogeneous populations of cells [20]. This evidence concerns the gene EGFR and neoplasm.